# A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)

> **NCT07136545** · PHASE1,PHASE2 · RECRUITING · sponsor: **Taipei Veterans General Hospital, Taiwan** · enrollment: 50 (estimated)

## Conditions studied

- HNSCC

## Interventions

- **DRUG:** HCB101
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07136545
- **Lead sponsor:** Taipei Veterans General Hospital, Taiwan
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-09-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07136545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07136545, "A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07136545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*